MedicaidPrior AuthMedium impact
Lunsumio® & Lunsumio Velo™ (mosunetuzumab-axgb) (New)
Humana·IN · Oncology, Hematology·Medicaid
Effective date
May 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Indiana Medicaid has established new prior authorization requirements for Lunsumio and Lunsumio Velo (mosunetuzumab-axgb), cancer medications used to treat relapsed or refractory follicular lymphoma. Prior authorization is required and will be approved for 6-month periods when specific clinical criteria are met.
Action Required
Before May 1, 2026: Billing team must update prior authorization workflows to require approval for Lunsumio and Lunsumio Velo (mosunetuzumab-axgb) for Indiana Medicaid patients. Providers must document follicular lymphoma diagnosis, relapsed/refractory disease status, at least two prior systemic therapies, and monotherapy use. Set up 6-month renewal reminders in system.